Germany bladder cancer market is estimated to grow considerably, at a CAGR of around 9.9% during the forecast period. Germany has a considerable market share in the global bladder cancer market due to the increasing geriatric population, presence of highly specialized urologists for cancer treatment and a bit lower cost treatment as compared to the UK, attracting medical tourism in the country. All these factors are contributing to the growth of the market. Germany has a well-developed healthcare system and favorable government policies which are driving the market in the region.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/germany-bladder-cancer-market
According to the World Health Organization (WHO), in 2018, the bladder cancer accounted for 5.9% of the overall new cases registered in Germany. Moreover, a total of 608,742 new cases of cancer were registered in 2018, among which, around 35,738 cases were registered for bladder cancer in the country. In the case of males, the incidence of bladder cancer registered higher as compared to the country average. It registered around 8.4% of the overall cases registered for men. Furthermore, the total number of deaths caused due to bladder cancer was nearly 8,874 in 2018 in Germany. These figures signify a significant potential for the growth of the market in Germany.
A full report of Germany Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/germany-bladder-cancer-market
Germany bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most commonly used method in the diagnosis and treatment of bladder cancer. The cystoscopy uses special tools that may be passed through cystoscope to treat very small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.
The companies which are contributing to the growth of the Germany bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
Germany Bladder Cancer Market- Segmentation
By Cancer type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Other Rare Types (Sarcomas, Carcinoma in Situ)
By Diagnosis Method
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (Ivp)
- Other
By Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Other
